The results showed that the levels of serum TAP and CEA in patients with thyroid cancer were significantly higher than those in patients with benign thyroid diseases, and the difference was statistically significant (P < 0.05). The gene discussed is CEACAM5; the disease is thyroid gland carcinoma.